Related Experiment Videos
Targeting cytotoxic T lymphocytes for cancer immunotherapy
1Cancer Research UK Breast Cancer Biology Group, Division of Cancer Studies, Guy's King's and St Thomas's School of Medicine, Guy's Hospital, St Thomas Street, London SE1 9RT, UK.
British Journal of Cancer
|July 22, 2004
Summary
Targeting cytotoxic T-lymphocytes (CTLs) is crucial for cancer immunotherapy. This review explores active and passive immunotherapeutic strategies, highlighting advances in tumor immunology and gene transfer for enhanced CTL-mediated cancer treatment.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Cytotoxic T-lymphocytes (CTLs) are key players in cellular immunity.
- Targeting CTLs for cancer treatment is an area of significant research interest.
- Advances in understanding tumor immunology are crucial for developing effective immunotherapies.
Purpose of the Study:
- To review active and passive immunotherapeutic approaches for targeting cytotoxic T-lymphocytes to cancer.
- To emphasize the impact of recent advances in tumor immunology on CTL-based cancer therapies.
- To discuss the role of gene transfer technologies in enhancing CTL-targeting strategies.
Main Methods:
- Literature review of active and passive immunotherapeutic strategies.
- Analysis of recent advancements in tumor immunology.
- Evaluation of gene transfer techniques for T-cell modification.
Main Results:
- Several active and passive immunotherapeutic approaches are under development.
- Recent progress in tumor immunology has provided new targets and strategies.
- Gene transfer offers promising avenues for improving CTL function and tumor infiltration.
Conclusions:
- Targeting cytotoxic T-lymphocytes is a promising strategy for cancer immunotherapy.
- Advances in tumor immunology and gene transfer are critical for developing effective CTL-based treatments.
- Further research is needed to optimize these approaches for clinical application.